Clinical Trial Update: BMS-247550 in Treating Patients With Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of BMS-247550 in patients with stage IV (recurrent) melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BMS-247550

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED